期刊文献+

Molecular docking and big-data bioinformatics predict the mechanisms of action of the active ingredients of Ganoderma lucidum in treating lung cancer

下载PDF
导出
摘要 Background:This study pioneers a network pharmacology-based approach and in silico molecular docking and visualization approaches to predict the potential molecular mechanisms involved in treatment of lung cancer with Lingzhi(Ganoderma lucidum).Methods:The active ingredients of Ganoderma lucidum were screened in the Traditional Chinese Medicine Systems Pharmacology database,and corresponding potential targets of these active ingredients were queried.Then potential targets for the treatment of lung cancer were separately queried using the GeneCards database.The overlapping targets of the active ingredients and lung cancer treatment were further analyzed in silico by calculating degree values and conducting literature searches.A protein-protein interaction network was constructed for these overlapping targets using the STRING database,and a“drug-ingredient-target”network was created using Cytoscape 3.7.1 software.Gene ontology and Kyoto Encyclopedia of Genes and Genomes(KEGG)enrichment analyses were performed for key targets using Metascape.Finally,the key molecules were examined using molecular docking in Autodock 3.7 software,and the representative docking results were visualized using PyMol software.Results:A total of 14 active ingredients were identified,including 3 key ingredients(ganolucidic acid E,ergosta-4,6,8(14),22-tetraene-3-one,and beta-sitosterol)and 8 key targets.Gene ontology analysis and KEGG enrichment showed that Ganoderma lucidum may act on 10 key signaling pathways,such as the neuroactive ligand-receptor interaction pathway,calcium signaling pathway,and cyclic adenosine monophosphate signaling pathway,to regulate neuroactivity,ion homeostasis,and other processes,thus inhibiting the progression of lung cancer.Molecular docking results predicted that among the 8 key targets,mu-type opioid receptor,transforming growth factor beta-1 proprotein,and apoptosis regulator BAX exhibit better docking with these ligands.Conclusion:The preliminary results of this study identified potential active ingredients of Ganoderma lucidum for the treatment of lung cancer,and putative mechanisms of action,which could provide a theoretical basis for further experimental studies on anticancer efficacy.
出处 《TMR Cancer》 2021年第1期19-29,共11页 TMR肿瘤
  • 相关文献

参考文献3

二级参考文献41

  • 1Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-917.
  • 2Jemal A, Bray F, Center MM, FerJay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
  • 3Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 2008; 83: 584-94.
  • 4Cotter TG. Apoptosis and cancer: the genesis of a re-search field. Nat Rev Cancer 2009; 9: 501-7.
  • 5Vermeulen K, Van Bockstaele DR, Berneman ZN. Ap-optosis: mechanisms and relevance in cancer. Ann He-mato12005; 84: 627-39.
  • 6Lowe SW, Lin A W. Apoptosis in cancer. Carcinogenesis 2000; 21: 485-95.
  • 7Singhal S, Vachani A, Antin-Ozerkis D, Kaiser LR, AI-belda SM. Prognostic implications of cell cycle, apopto-sis, and angiogenesis biomarkers in non-small cell lung cancer: a review. Clin Cancer Res 2005; 11: 3974-86.
  • 8Nuckel H, Frey UH, Bau M, Sellmann L, Stanelle J, Durig J, et al. Association of a novel regulatory poly-morphism (-938C>A) in the BCL2 gene promoter with disease progression and survival in chronic lymphocytic leukemia. Blood 2007; 109: 290-7.
  • 9Bachmann HS, Otterbach F, Callies R, Nuckel H, Bau M, Schmid KW, et al. The AA genotype of the regulatory BCL2 promoter polymorphism ( 938C>A) is associated with a favorable outcome in lymph node negative inva-sive breast cancer patients. Clin Cancer Res 2007; 13: 5790-7.
  • 10Lehnerdt GF, Franz P, Bankfalvi A, Grehl S, Kelava A, Nuckel H, et al. The regulatory BCL2 promoter poly-morphism (-938C>A) is associated with relapse and survival of patients with oropharyngeal squamous cell carcinoma. Ann Onco12009; 20: 1094-9.

共引文献119

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部